ACR/ARHP 2016 Annual Meeting

Sustained Disease Control Seen With Long-Term Belimumab in SLE

By

Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.

ACR/ARHP 2016 Annual Meeting

Smoking Leads to Worse RA Flare and Remission Patterns

By

Tobacco smoking adversely impacts rheumatoid arthritis (RA) flare and remission rates, according to findings from a long-term retrospective, population-based cohort study, presented at the 2016 ACR/ARHP Annual Meeting.

ACR/ARHP 2016 Annual Meeting

Temporary MTX Discontinuation Ups Flu Vaccine Efficacy in RA

By

Temporarily discontinuing methotrexate (MTX) treatment can improve seasonal influenza vaccination immunogenicity among patients with rheumatoid arthritis (RA), according to a single center, randomized, single-blind, open-label prospective study (NCT02748785) presented at the 2016 ACR/ARHP Annual Meeting.

ACR/ARHP 2016 Annual Meeting

Infliximab vs. Biosimilar: Discontinuation Rates Compared

By

Medical records of 1,044 patients with RA, new to starting treatment with Remicade or CT-P13, were analyzed in the study.

ACR/ARHP 2016 Annual Meeting

Anti-TNF Agents Go Head-to-Head in RA Superiority Study

By

The trial compares short- and long-term outcomes of Cimzia and Humira in RA

ACR/ARHP 2016 Annual Meeting

Tofacitinib Effective in PsA Patients With Prior Inadequate Response

By

Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study

ACR/ARHP 2016 Annual Meeting

Large RA Survey Finds 61% of Patients Uncomfortable Voicing Concerns

By

Results from a global survey given to patients and physicians showed that good communication is "critical to achieve optimal care".

ACR/ARHP 2016 Annual Meeting

Sarilumab Offers Durable Clinical Responses for RA After 3 Years

By

The IL-6Rα -targeting human mAb sarilumab offers durable responses against rheumatoid arthritis (RA), according to an analysis of 3-year clinical and radiographic outcomes and safety for patients from the MOBILITY open-label extension study.

ACR/ARHP 2016 Annual Meeting

Sarilumab Efficacy, Safety Comparable Among RA Patient Subgroups

By

The IL-6Rα -targeting human mAb sarilumab exhibits comparable efficacy and safety for different patient subgroups in rheumatoid arthritis.

ACR/ARHP 2016 Annual Meeting

Long-Term Adalimumab Reduces Uveitis and Corticosteroid Dose

By

Adalimumab (Humira) helps treat non-infectious intermediate, posterior, or panuveitis (NIPPU), according to findings from an open-label clinical trial extension, VISUAL-III